154 related articles for article (PubMed ID: 35486885)
1. Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer.
Aslan V; Sütcüoğlu O; Özet A; Özdemir N; Yazıcı O
J Clin Oncol; 2022 Jul; 40(19):2177-2178. PubMed ID: 35486885
[No Abstract] [Full Text] [Related]
2. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O'Malley DM; Neffa M; Monk BJ; Melkadze T; Huang M; Kryzhanivska A; Bulat I; Meniawy TM; Bagameri A; Wang EW; Doger de Speville Uribe B; Hegg R; Ortuzar Feliu W; Ancukiewicz M; Lugowska I
J Clin Oncol; 2022 Mar; 40(7):762-771. PubMed ID: 34932394
[TBL] [Abstract][Full Text] [Related]
3. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O'Malley DM; Randall LM; Jackson CG; Coleman RL; Hays JL; Moore KN; Naumann RW; Rocconi RP; Slomovitz BM; Tewari KS; Ancukiewicz M; Feliu WO; Monk BJ
Future Oncol; 2021 Sep; 17(26):3433-3443. PubMed ID: 34409858
[TBL] [Abstract][Full Text] [Related]
4. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
8. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report.
Ustaalioglu BB; Bilici A; Seker M; Canpolat N; Ozdemir N; Salepci T; Gumus M
Leuk Res; 2010 Apr; 34(4):e108-10. PubMed ID: 19931906
[No Abstract] [Full Text] [Related]
9. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
10. The role of chemotherapy in cervical cancer--a review.
Sivanesaratnam V
Singapore Med J; 1988 Aug; 29(4):397-401. PubMed ID: 3074519
[No Abstract] [Full Text] [Related]
11. Cediranib aims for a comeback.
Schmidt C
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745013
[No Abstract] [Full Text] [Related]
12. Update on novel therapeutic agents for cervical cancer.
del Campo JM; Prat A; Gil-Moreno A; Pérez J; Parera M
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S72-6. PubMed ID: 18544460
[TBL] [Abstract][Full Text] [Related]
13. Management of advanced or recurrent cervical cancer: chemotherapy and beyond.
Elit LM; Hirte H
Expert Rev Anticancer Ther; 2014 Mar; 14(3):319-32. PubMed ID: 24428511
[TBL] [Abstract][Full Text] [Related]
14. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
15. [Chemoradiotherapy: innovation in treatment of high-risk cervical cancer].
Piura B; Meirovitz M
Harefuah; 2000 Mar; 138(6):482-7. PubMed ID: 10883165
[No Abstract] [Full Text] [Related]
16. [Chemotherapy of carcinoma of the cervix uteri. Current approaches].
Sesti F; Mantenuto L; Ciancaglini G; Araco P; De Santis L; Piccione E
G Ital Oncol; 1989; 9(4):125-8. PubMed ID: 2693349
[TBL] [Abstract][Full Text] [Related]
17. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy.
Thomas GM
N Engl J Med; 1999 Apr; 340(15):1198-200. PubMed ID: 10202172
[No Abstract] [Full Text] [Related]
18. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in cervical cancer: is cisplatin alone still the standard of care?
Tattersall MH
Ann Oncol; 2001 Jul; 12(7):883. PubMed ID: 11521790
[No Abstract] [Full Text] [Related]
20. [II. Current Topics and Perspective of Chemotherapy for Uterine Cervical Cancer].
Kitagawa R; Nakanishi T; Fukaya T; Watanabe Y
Gan To Kagaku Ryoho; 2017 Feb; 44(2):126-130. PubMed ID: 28676622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
